Latest European Expansion News

Iondrive Ltd reported a 94.7% surge in revenue to $1.71 million for FY2025, driven by R&D tax incentives and other income, yet still recorded a net loss of $4.62 million amid high expenses. The company also expanded its footprint in Europe by acquiring a German entity.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

AML3D has appointed German firm DMFG Solutions as a second European distributor, complementing its recent UK partnership and supporting a AU$5 million investment in a new technology centre.

Argent BioPharma has achieved a significant milestone by commencing formal supply of its EU-GMP cannabinoid API for epilepsy treatment at a leading Slovenian hospital and gaining prescription approval for CannEpil™ in Germany, marking key steps in its European expansion.

International Graphite Limited (ASX, IG6) has signed a cooperation agreement to develop a 3,000 t/y expandable graphite facility in Germany, advancing its global footprint alongside progress at its Collie micronising plant and Springdale project, supported by potential US Department of Defense funding.

Iondrive Limited advances its proprietary battery recycling technology with a pilot plant design, European consortium formation, and new e-waste initiatives, supported by significant grant funding.

International Graphite Limited (ASX – IG6) has had its trading suspension lifted following the announcement of a new agreement to develop a graphite processing facility in Europe.

AML3D has appointed Arc Additive as its UK and European distribution partner, marking a strategic push into key manufacturing and defence markets across Europe. This move follows a successful capital raise and a contract with BAE Systems UK, underpinning AML3D’s growth ambitions.

UNITH Ltd reported a record quarterly cash receipt of $1.6 million in Q4 FY25, driven by strategic partnerships and platform innovations. The company is poised for growth with a new website launch and expanded European presence.

AML3D Limited reports a 77% jump in US customer receipts and secures a pivotal US Navy Letter of Intent worth up to $200 million, underpinning its rapid expansion in defence manufacturing.

Bioxyne Limited reports a record-breaking Q4 FY25 with revenue soaring 204% year-on-year and a strategic entry into the German market through a €3.2 million manufacturing agreement.

Little Green Pharma reported a robust June 2025 quarter with record cash receipts and expanding European footprint, highlighted by a new production capacity in Denmark and the launch of its CherryCo brand in Germany.